Goldman Cuts Cubist Pharmaceuticals (CBST) to Neutral, Concerned about Execution
Tweet Send to a Friend
Goldman Sachs downgraded Cubist Pharmaceuticals (NASDAQ: CBST) from Conviction Buy to Neutral with a price target of $59.00. On ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
